CPIX Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals, Inc. has a net margin of -23.5% compared to Cumberland Pharmaceuticals, Inc.'s net margin of 20.1%. Cumberland Pharmaceuticals, Inc.'s return on equity of -12.95% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.

Cumberland Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 120.21%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $479.79 which suggests that it could grow by 48.55%. Given that Cumberland Pharmaceuticals, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Cumberland Pharmaceuticals, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..

Cumberland Pharmaceuticals, Inc. has a beta of -0.524, which suggesting that the stock is 152.43% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.

Cumberland Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cumberland Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Cumberland Pharmaceuticals, Inc. quarterly revenues are $8.3M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. Cumberland Pharmaceuticals, Inc.'s net income of -$1.9M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, Cumberland Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,342.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cumberland Pharmaceuticals, Inc. is 1.38x versus 13.25x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

ImmuCell Corp. has a net margin of -23.5% compared to Cumberland Pharmaceuticals, Inc.'s net margin of -2.54%. Cumberland Pharmaceuticals, Inc.'s return on equity of -12.95% beat ImmuCell Corp.'s return on equity of 8.15%.

Cumberland Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 120.21%. On the other hand ImmuCell Corp. has an analysts' consensus of -- which suggests that it could grow by 111.16%. Given that Cumberland Pharmaceuticals, Inc. has higher upside potential than ImmuCell Corp., analysts believe Cumberland Pharmaceuticals, Inc. is more attractive than ImmuCell Corp..

Cumberland Pharmaceuticals, Inc. has a beta of -0.524, which suggesting that the stock is 152.43% less volatile than S&P 500. In comparison ImmuCell Corp. has a beta of 0.300, suggesting its less volatile than the S&P 500 by 70.041%.

Cumberland Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ImmuCell Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cumberland Pharmaceuticals, Inc. pays -- of its earnings as a dividend. ImmuCell Corp. pays out -- of its earnings as a dividend.

Cumberland Pharmaceuticals, Inc. quarterly revenues are $8.3M, which are larger than ImmuCell Corp. quarterly revenues of $5.5M. Cumberland Pharmaceuticals, Inc.'s net income of -$1.9M is lower than ImmuCell Corp.'s net income of -$139.7K. Notably, Cumberland Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while ImmuCell Corp.'s PE ratio is 25.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cumberland Pharmaceuticals, Inc. is 1.38x versus 2.15x for ImmuCell Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -23.5% compared to Cumberland Pharmaceuticals, Inc.'s net margin of 18.06%. Cumberland Pharmaceuticals, Inc.'s return on equity of -12.95% beat Merck & Co., Inc.'s return on equity of 39.63%.

Cumberland Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 120.21%. On the other hand Merck & Co., Inc. has an analysts' consensus of $122.23 which suggests that it could grow by 4.34%. Given that Cumberland Pharmaceuticals, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Cumberland Pharmaceuticals, Inc. is more attractive than Merck & Co., Inc..

Cumberland Pharmaceuticals, Inc. has a beta of -0.524, which suggesting that the stock is 152.43% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.280, suggesting its less volatile than the S&P 500 by 72.042%.

Cumberland Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.8% to investors and pays a quarterly dividend of $0.85 per share. Cumberland Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cumberland Pharmaceuticals, Inc. quarterly revenues are $8.3M, which are smaller than Merck & Co., Inc. quarterly revenues of $16.4B. Cumberland Pharmaceuticals, Inc.'s net income of -$1.9M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Cumberland Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 16.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cumberland Pharmaceuticals, Inc. is 1.38x versus 4.52x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Savara, Inc. has a net margin of -23.5% compared to Cumberland Pharmaceuticals, Inc.'s net margin of --. Cumberland Pharmaceuticals, Inc.'s return on equity of -12.95% beat Savara, Inc.'s return on equity of -78.83%.

Cumberland Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 120.21%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 105.17%. Given that Cumberland Pharmaceuticals, Inc. has higher upside potential than Savara, Inc., analysts believe Cumberland Pharmaceuticals, Inc. is more attractive than Savara, Inc..

Cumberland Pharmaceuticals, Inc. has a beta of -0.524, which suggesting that the stock is 152.43% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.

Cumberland Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cumberland Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.

Cumberland Pharmaceuticals, Inc. quarterly revenues are $8.3M, which are larger than Savara, Inc. quarterly revenues of --. Cumberland Pharmaceuticals, Inc.'s net income of -$1.9M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Cumberland Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cumberland Pharmaceuticals, Inc. is 1.38x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.